An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management

J. Davies; A. Ingham

doi:10.1016/j.ijpharm.2015.03.055

An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management

J. Davies, A. Ingham^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

Original language	English
Pages (from-to)	101-109
Number of pages	9
Journal	International Journal of Pharmaceutics
Volume	487
Issue number	1-2
Early online date	30 Mar 2015
DOIs	https://doi.org/10.1016/j.ijpharm.2015.03.055
Publication status	Published - 20 Jun 2015

Bibliographical note

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).

Funding: European Union’s Seventh Framework Programme managed by REA Research Executive Agency http://ec.europa.eu/rea (FP7/2007-2013) under grant Project Reference 286852.

Keywords

BPR
cholecalciferol
efficacy
regulation No. 528/2012
transdermal
rodenticide

Access to Document

10.1016/j.ijpharm.2015.03.055

Model for the transdermal delivery of cholecalciferol for the purposes of rodent management
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).
Final published version, 537 KBLicence: CC BY-NC-ND 3.0

Cite this

@article{762aa09aa8d54dacb522a5ae9aa87192,

title = "An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management",

abstract = "The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).",

keywords = "BPR, cholecalciferol, efficacy, regulation No. 528/2012, transdermal, rodenticide",

author = "J. Davies and A. Ingham",

note = "Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). Funding: European Union{\textquoteright}s Seventh Framework Programme managed by REA Research Executive Agency http://ec.europa.eu/rea (FP7/2007-2013) under grant Project Reference 286852.",

year = "2015",

month = jun,

day = "20",

doi = "10.1016/j.ijpharm.2015.03.055",

language = "English",

volume = "487",

pages = "101--109",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management

AU - Davies, J.

AU - Ingham, A.

N1 - Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). Funding: European Union’s Seventh Framework Programme managed by REA Research Executive Agency http://ec.europa.eu/rea (FP7/2007-2013) under grant Project Reference 286852.

PY - 2015/6/20

Y1 - 2015/6/20

N2 - The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

AB - The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

KW - BPR

KW - cholecalciferol

KW - efficacy

KW - regulation No. 528/2012

KW - transdermal

KW - rodenticide

UR - http://www.scopus.com/inward/record.url?scp=84927718041&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2015.03.055

DO - 10.1016/j.ijpharm.2015.03.055

M3 - Article

AN - SCOPUS:84927718041

SN - 0378-5173

VL - 487

SP - 101

EP - 109

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

IS - 1-2

ER -

An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this